A Genome-Wide siRNA Screen to Identify Modulators of Insulin Sensitivity and Gluconeogenesis by Yang, Ruojing et al.
A Genome-Wide siRNA Screen to Identify Modulators of
Insulin Sensitivity and Gluconeogenesis
Ruojing Yang
1*, Raul G. Lacson
2, Gino Castriota
1, Xiaohua D. Zhang
3, Yaping Liu
2, Wenqing Zhao
4,
Monica Einstein
1, Luiz Miguel Camargo
1, Sajjad Qureshi
1, Kenny K. Wong
5, Bei B. Zhang
1, Marc Ferrer
2,
Joel P. Berger
1*
1Department of Metebolic Disorders-Diabetes, Merck Research Laboratories, Rahway, New Jersey, United States of America, 2Cell Based HTS, Merck Research
Laboratories, North Wales, Pennsylvania, United States of America, 3Biometrics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of
America, 4Department of Guided Solutions, Merck Research Laboratories, Rahway, New Jersey, United States of America, 5Department of Atherosclerosis, Merck
Research Laboratories, Rahway, New Jersey, United States of America
Abstract
Background: Hepatic insulin resistance impairs insulin’s ability to suppress hepatic glucose production (HGP) and
contributes to the development of type 2 diabetes (T2D). Although the interests to discover novel genes that modulate
insulin sensitivity and HGP are high, it remains challenging to have a human cell based system to identify novel genes.
Methodology/Principal Findings: To identify genes that modulate hepatic insulin signaling and HGP, we generated a
human cell line stably expressing beta-lactamase under the control of the human glucose-6-phosphatase (G6PC) promoter
(AH-G6PC cells). Both beta-lactamase activity and endogenous G6PC mRNA were increased in AH-G6PC cells by a
combination of dexamethasone and pCPT-cAMP, and reduced by insulin. A 4-gene High-Throughput-Genomics assay was
developed to concomitantly measure G6PC and pyruvate-dehydrogenase-kinase-4 (PDK4) mRNA levels. Using this assay, we
screened an siRNA library containing pooled siRNA targeting 6650 druggable genes and identified 614 hits that lowered
G6PC expression without increasing PDK4 mRNA levels. Pathway analysis indicated that siRNA-mediated knockdown (KD) of
genes known to positively or negatively affect insulin signaling increased or decreased G6PC mRNA expression, respectively,
thus validating our screening platform. A subset of 270 primary screen hits was selected and 149 hits were confirmed by
target gene KD by pooled siRNA and 7 single siRNA for each gene to reduce G6PC expression in 4-gene HTG assay.
Subsequently, pooled siRNA KD of 113 genes decreased PEPCK and/or PGC1alpha mRNA expression thereby demonstrating
their role in regulating key gluconeogenic genes in addition to G6PC. Last, KD of 61 of the above 113 genes potentiated
insulin-stimulated Akt phosphorylation, suggesting that they suppress gluconeogenic gene by enhancing insulin signaling.
Conclusions/Significance: These results support the proposition that the proteins encoded by the genes identified in our
cell-based druggable genome siRNA screen hold the potential to serve as novel pharmacological targets for the treatment
of T2D.
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Introduction
Insulin resistance in liver, skeletal muscle, and fat leads to the
development of type 2 diabetes (T2D) [1,2]. In addition, insulin
resistance is closely associated with central obesity, dyslipidemia,
atherosclerosis, hypertension, and inflammation [3]. Hepatic
insulin resistance results in excessive hepatic glucose production
(HGP), which plays a major role in the development of
hyperglycemia. Conversely, diminution of HGP by various anti-
diabetic agents reduces hyperglycemia in humans and preclinical
species. The major action of metformin, a first-line T2D
therapeutic agent, is to reduce elevated HGP, although the
molecular mechanism mediating this beneficial action is not fully
understood [4,5,6]. Inhibition of glucagon action by glucagon-
neutralizing antibodies, antagonistic glucagon peptide analogs, or
glucagon receptor (GCGR) anti-sense oligonucleotides inhibit
HGP and reduce blood glucose levels in diabetic animals
[7,8,9,10,11]. Additionally, small molecule GCGR antagonists
inhibit glucagon-induced increases of blood glucose in humans
and animals [12,13,14,15]. Taken together, these results indicate
that enhancing hepatic insulin sensitivity and decreasing gluco-
neogenesis (GNG) suppresses HGP and, therefore, reduces
diabetic hyperglycemia.
Insulin suppresses HGP by both direct and indirect means,
which then mitigates fasting hyperglycemia, impaired glucose
tolerance, and postprandial hyperglycemia [16]. Much has been
learned in recent years about the molecular mechanisms
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receptor knockout (LIRKO) mice display complete blockage of the
hepatic insulin signaling pathway and fail to suppress HGP in
response to treatment with exogenous insulin [17]. LIRKO mice
develop severe insulin resistance, hyperglycemia, and hyperinsu-
linemia. Insulin suppresses the expression of several key GNG
regulatory genes, including glucose-6-phosphatase (G6PC), phos-
phoenolpyruvate carboxylase (PEPCK), and fructose-1,6-bisphos-
phatase [18,19]. Several lines of evidence have shown that folk-
head transcription factor (Foxo1) binds to the promoter region of
several GNG genes to activate their transcription, and this
interaction can be blocked by insulin treatment [20,21,22]. Insulin
triggers the phosphorylation of Foxo1 via the PI3-kinase-depen-
dent Akt pathway resulting in the exclusion of Foxo1 from the
nucleus, and consequently, decreased transcription of its GNG
target genes [23,24,25]. The peroxisome proliferator-activated
receptor-c coactivator-1a (PGC-1a) functions as a master regula-
tor of GNG gene expression in liver [26], binding to and activating
Foxo1, hepatocyte nuclear factor (HNF)-4a, and glucocorticoid
receptor (GR), and thereby fully activating the transcription of
GNG genes [26,27]. Recent studies have demonstrated that
insulin directly inhibits PGC-1a activity through Akt-mediated
phosphorylation of the co-activator [28]. Insulin also blocks PGC-
1a induction of GNG gene expression by disrupting the
interaction of PGC-1a and FoxO1 [27].
To discover novel genes that modulate insulin sensitivity and
HGP, we developed a high throughput human hepatoma-based
G6PC/PDK4 gene expression assay and used it to screen a library
containing synthetic small interference RNA (siRNAs) for 6650
genes encoding druggable protein targets. Additional distinct
secondary assays were utilized to confirm our primary hits, and
identify those that modulate expression of key GNG genes in
addition to G6PC and insulin signaling. Lastly, we demonstrated
that the GR antagonist RU-486, which has previously been shown
to diminish HGP and hyperglycemia in diabetic animals [29] can
suppress G6PC expression in our cell-based assay in a manner
comparable to knocking down that receptor.
Results
To identify novel drug targets that have the potential to
enhance insulin sensitivity and decrease HGP, we generated a
human hepatoma cell line, AH-G6PC, that stably expressed b-
lactamase under the control of the G6PC promoter (Fig. 1A) as
described in the ‘‘Experimental Procedures’’ section. This cell
line also expressed readily assayable levels of endogenous G6PC
mRNA (Fig. 1A). It has previously been demonstrated that
G6PC is transcriptionally upregulated by glucagon, catechol-
amines, glucocorticoids, and downregulated by insulin [30].
Therefore, to examine the hormonal responsiveness of our AH-
G6PC cell line, we treated them with 500 nM dexamethasone
and a cAMP analogue (pCPT-cAMP) at a concentration of
100 uM (Dex/cAMP) to activate the G6PC promoter and
examined the effect of increasing concentrations of insulin on b-
lactamase activity and endogenous G6PC mRNA expression. As
shown in Fig. 1B, Dex/cAMP increased b-lactamase activity by
1.7-fold compared to basal condition (no Dex/cAMP condition)
and insulin dose-dependently suppressed its activity.
While the b-lactamase readout was utilized in developing the
basic AH-G6PC cell assay protocol, it did not provide a sufficient
dynamic range for use in our high throughput siRNA library
screen. In contrast, Taqman analysis showed that Dex/cAMP
treatment induced a 10-fold increase in endogenous G6PC mRNA
levels, while insulin dose-dependently reduced G6PC mRNA to
basal levels with IC50 of ,40 nM (Fig. 1C). Based on these results,
we selected Dex/cAMP plus 10 nM insulin as the cell incubation
condition for our screen since this concentration of insulin only
weakly diminished the robust induction of G6PC expression by
Dex/cAMP thereby providing considerable sensitivity to demon-
strate potentiation of insulin action by siRNA gene KD. AH-
G6PC cells transfected with control siRNA (siControl) responded
as expected to Dex/cAMP and insulin in regulating the levels
G6PC mRNA, indicating that siRNA transfection per se did not
negatively affect our assay system (Fig. 1C). GR siRNA (siGR)
knocked down GR mRNA by 95% (data not shown) and, as
anticipated, led to a large reduction in Dex/cAMP-induced G6PC
mRNA expression in cells incubated with vehicle or a wide range
of insulin concentrations (Fig. 1C). In additional studies, we found
that chronic incubation of AH-G6PC cells with either of the 2
antidiabetic drugs, metformin or rosiglitazone, significantly
reduced G6PC mRNA (Fig. 1D) without causing any measurable
cytotoxicity (not shown). These data indicated that AH-G6PC cells
respond appropriately to metabolic hormones and anti-diabetic
drugs known to suppress HGP or enhance insulin sensitivity in
T2D patients.
To screen our siRNA library, we developed a multiplex High
Throughput Genomics (HTG) array that could concomitantly
measure the mRNA levels of 4 genes in each well of a 384-well
plate. In addition to G6PC, we selected pyruvate dehydrogenase
kinase 4 (PDK4) as another test gene, b-actin as the housekeep-
ing gene with which to normalize the above test gene data, and a
plant gene, ANT, as the negative control (Fig. 2A). PDK4
functions as a metabolic switch gene that phosphorylates and
inhibits pyruvate dehydrogenase which, in turn, increases GNG
and decreases glycolysis. PDK4 is upregulated in diabetic or
fasting animals, and is downregulated by insulin or refeeding
[31]. Dex/cAMP-induced AH-G6PC cell expression of both
G6PC and PDK4 mRNA was dose-dependently reduced by
insulin in our HTG assay (Fig. 2B) with similar IC50s of 24 and
37 nM, respectively. However, the assay window of PDK4 (3-
fold) was substantially smaller than that of G6PC (10-fold) due to
diminished effects by both Dex/cAMP and insulin on expression
of the former gene relative to the latter (Fig. 2B). Thus, we
selected G6PC as the primary readout to identify siRNA screen
hits, while PDK4 was used to remove preliminary hits that
regulated G6PC and PDK4 expression in opposite directions,
since they could have unpredictable effects on HGP. b-actin
expression was used not only to normalize changes in G6PC and
PDK4 expression but also to identify and remove cytotoxic
siRNAs since diminished expression of b-actin correlated well
with cytotoxicity (not shown). We screened an siRNA library
containing pooled siRNAs to each of 6650 druggable genes (3
distinct siRNAs/gene) and defined a primary hit as any gene
whose siRNA pool caused a $30% increase or reduction in
G6PC mRNA expression and an SSMD greater than a certain
absolute value (See the Section of Statistical Analysis for more
details). Using this approach, our screen identified 614 and 537
hits that decreased or increased G6PC mRNA levels, respectively
(Fig. 2C).
Pathway analysis was performed on the above hits as
described in the ‘‘Experimental Procedures’’ section and we
found that the insulin signaling pathway contained the greatest
number of siRNA target genes that regulated G6PC expression.
It is well-documented that insulin binds to the hepatocyte
insulin receptor (INSR) to increase tyrosine phosphorylation of
INSR and insulin receptor substrates (IRS). Tyrosine-phosphor-
ylated IRS proteins bind to and activate phosphatidylinositol 3-
kinase (PI3K), which increases phosphatidylinositol-3,4
A Novel Approach to Identify Insulin Sensitizers
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levels that, in turn, activate phosphoinositide-dependent kinase
1 (PDK1). PDK1 then phosphorylates and activates the kinase
Akt, which subsequently suppresses GNG (Fig. 2D). As shown
schematically in Figure 2D and quantitatively in Table 1,
transfection of siRNAs targeting INSR, IRS2, PDK1, PI3-K
subunits (p85b or pl10a), or AKT2 significantly upregulated
G6PC mRNA expression (1.6- to 2.2-fold). Phosphatase and
tensin homologue (PTEN) is a phosphatase that inhibits the
insulin pathway by dephosphorylating PtdIns(3,4,5)P3 to
PtdIns(4,5)P2. PTEN siRNAs significantly reduced G6PC
mRNA levels in AH-G6PC cells (Table 1). Suppressor of
cytokine signaling protein 1 and 3 (SOCS1 and SOCS3) bind
to INSR and IRS thereby inhibiting hepatocyte insulin
signaling; their siRNAs significantly reduced G6PC expression
(Table 1). Insulin signaling activates mammalian target of
rapamycin (mTOR) and ribosomal protein S6 kinase (p70S6K),
which then activates several downstream serine kinases including
c-Jun N-terminal kinase (JNK1), NF-kB inhibitor kinase beta
(IKKb), and protein kinase C (PKC) all of which inhibit insulin
signaling by serine phosphorylation of IRS [32]. Our screening
results demonstrated that mTOR, JNK1, IKKb, and atypical
protein kinase C-zeta (PKCf) siRNAs significantly reduced
G6PC mRNA levels, consistent with their negative regulatory
role on insulin signal transduction. Taken together, these results
substantiated our screening platform as a means to identify
genes that potentiate insulin sensitivity and inhibit HGP.
Hit Confirmation
Our initial screen identified 614 hits whose siRNAs down-
regulated G6PC mRNA expression by more than 30%. Utilizing
available literature and databases, we determined the known
biological functions, human disease associations, and druggability
for all of these genes and selected 270 targets for further
confirmation based on their superior characteristics.
The most commonly used strategy to confirm primary hits from
a pooled siRNA screen is to reproduce the results using several
distinct single siRNAs. The concept behind this strategy is that if 2
or more different siRNAs for the same gene reduce G6PC mRNA
expression, the chance that this is an off-target effect is
considerably reduced and, therefore, the hit is confirmed. To
evaluate the single siRNA strategy for the next step in the
confirmation of our primary hits, we compared the ability of pools
containing 4 siRNAs vs. sets of 4 single siRNAs to knock down the
expression of several representative target genes and downregulate
G6PC mRNA levels. As shown in figure 3A, KD of IKKb, JNK1,
PTEN, GR, and glycogen phosphorylase (PYGL) mRNAs by
pooled siRNAs was much more robust than by any single siRNA.
With regard to G6PC expression, we found that the pooled
siRNAs for IKKb, JNK1, GR, PTEN, and PYGL were able to
reduce G6PC mRNA levels by $30% (Fig. 3B). There were at
least 2 single siRNAs for IKKb, GR, and PTEN that reduced
G6PC by $30%. However, none and only 1 of the single siRNAs
for JNK1 and PYGL, respectively, were able to reduce G6PC
mRNA by $30%. Furthermore, we tested additional 8 hits from
Figure 1. Generation of the hormone-responsive human hepatoma cell line, AH-G6PC, and optimization of assay conditions for
siRNA transfection. A. AH-G6PC cells express both the reporter gene, b-lactamase, under the control of the G6PC promoter and endogenous G6PC.
B. Insulin dose-responsively decreases Dex/cAMP activation of b-lactamase activity. C. Changes in endogenous G6PC mRNA levels in AH-G6PC cells
treated with vehicle (basal), Dex/cAMP, Dex/cAMP after transfection with control siRNAs (siControl), or Dex/cAMP after transfection with
glucocorticoid receptor siRNAs (siGR), and increasing concentrations of insulin. D. Incubation of AH-G6PC cells with metformin (667 mM) for 16 h or
rosiglitazone (10 uM) for 6 h reduces G6PC mRNA expression. Data are shown as the means 6 SEM fold change relative to basal (no Dex/cAMP or
insulin) in a study performed in triplicate, and is representative of multiple experiments. *, P,0.05 by Student’s t-test vs. Dex/cAMP-treated samples.
doi:10.1371/journal.pone.0036384.g001
A Novel Approach to Identify Insulin Sensitizers
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36384the screen for the target gene knockdown and G6PC mRNA
reduction in AH-G6PC cells. Consistently, the pooled siRNAs
knocked down target genes better than each single siRNA, which,
in turn, led to a greater reduction in G6PC mRNA expression by
the pooled vs. the single siRNAs. Among the 8 genes we tested,
there were 2 genes that had 2 single siRNAs reducing G6PC
mRNA by $30%, 3 genes that had 1 single siRNAs reducing
G6PC mRNA by $30%, and 3 genes without a single siRNA
lowering G6PC mRNA by $30%. However, 7 out of 8 genes had
more than 2 single siRNAs lowering G6PC mRNA by $20%.
These data suggest that the reduced knockdown potency by single
siRNAs compared to the pooled siRNAs led to less reduction of
G6PC mRNA in AH-G6PC cells. Since we were using a 30%
reduction in G6PC mRNA as the minimum cutoff for hit
selection, the above data `indicated that using single siRNAs
would have likely resulted in numerous false negatives (e.g. JNK1
and PYGL) due to ineffective KD of the target genes. Therefore,
we used a pooled not a single siRNA protocol in our first hit
confirmation assay.
To confirm the primary hits, it was decided that a target gene
would have to be observably expressed in AH-G6PC cells and its
measurable KD associated with a reduction in G6PC mRNA
expression. Therefore, we developed a high-throughput Taqman
qPCR analysis protocol to confirm target gene KD as well as
diminished G6PC expression using the same mRNA samples.
Specifically, we transfected pooled siRNA into AH-G6PC cells
cultured in 96- instead of 384-well plates to increase the amount of
mRNA available for Taqman assays of the 270 primary hits.
Nevertheless, we could only detect the expression of 165 genes, of
which 126 (red) and 25 (blue) genes were knocked down by .4-
fold and between 2- to 4-fold, respectively, by their siRNA pools.
There were only 4 sets (green) of pooled siRNAs that did not KD
Figure 2. Screening of a druggable siRNA library with a 4-gene High-Throughput-Genomics (HTG) assay. A. Layout of genes within
each well of a 4-gene HTG 384-well ArrayPlate. B. Insulin dose-responsively inhibits Dex/cAMP induction of G6PC and PDK4 mRNA expression in AH-
G6PC cells when assayed by the HTG platform. Data are presented as the means 6 SEM of a study performed in triplicate; similar results were
obtained in 4 independent experiments. C. Dual-flashlight plot comparing SSMD values vs. average fold change in G6PC mRNA expression by all
siRNA pools in the library in order to select hits that regulate G6PC mRNA levels. Glucocorticoid receptor (GR) siRNAs were used as positive controls in
each plates (red dots), while non-targeting siRNAs were used as negative controls in each plate (green dots). The blue square and the small rectangle
represent the up-regulators with G6PC $2 and SSMD $1 and G6PC $1.3 and SSMD $2, respectively. The orange square and the small rectangle
represent the down-regulators with G6PC#1/2 and SSMD#21 and G6PC#0.7 and SSMD#22, respectively. D. Major proximal molecular mediators
and key negative modulators of hepatic insulin signaling. siRNA knockdown of target genes that lowered and increased G6PC mRNA expression are
indicated in orange and blue, respectively.
doi:10.1371/journal.pone.0036384.g002
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Symbol Gene_ID
G6PC mRNA (Fold vs.
siControl)
PDK4 mRNA (Fold vs.
siControl)
Insulin signaling components INSR 3643 1.61* 1.88*
IRS2 8660 2.08* 1.36*
AKT2 208 2.03* 0.88
PDK1 5170 2.09* 1.44*
p110-alpha 5290 2.09* 1.72*
p85-beta 5296 2.23* 1.3*
Negative regulators of insulin signaling PTEN 5728 0.36* 0.71*
SOCS1 8651 0.67* 0.7*
SOCS3 9021 0.76* 0.52*
mTOR 2475 0.51* 0.82*
JNK1 5599 0.55* 0.76*
IKKbeta 3551 0.61* 1.08
PKC-zeta 5590 0.6* 0.69*
*Gene expressios are significantly increased or decreased compared to siControl treated samples with p,0.05.
doi:10.1371/journal.pone.0036384.t001
Figure 3. Pooled siRNAs demonstrate greater knockdown efficacy than single siRNAs. Comparison of the ability of transfected pooled vs.
single siRNAs to A. knockdown target gene mRNA levels and B. reduce G6PC mRNA levels in AH-G6PC cells incubated with Dex/cAMP and 10 nM
insulin for 6 h. Black bars are pooled siRNA samples; grey bars are single siRNA samples. Data are presented as fold changes relative to mRNA
expression in siControl-transfected cells and are the means of 3 independent experiments for A and B.
doi:10.1371/journal.pone.0036384.g003
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genes by 1.2- to 2-fold. With regard to the siRNA pools targeting
the 165 detectable genes, 112 reduced G6PC expression by
$30%, among which 106 and 5 knocked down their target gene
by .2-fold and 1.2- to 2-fold, respectively (Fig. 4A). These 111 hits
were considered confirmed. Additionally, 14 hits whose siRNAs
caused $2-fold KD of their target gene but only a 20–30%
reduction in G6PC mRNA expression were selected as back-up
hits.
Since the amount of mRNA that could be extracted from cells
plated in 96-well was limited, the inability to detect 105 primary
hits above by Taqman analysis was likely due to their relatively
low expression levels. Indeed, when we used highly enriched
mRNA prepared from AH-G6PC cells cultured in T75-flasks in
our qPCR reactions, we confirmed that 254 of the 270 primary
hits were expressed. Amongst the pooled siRNAs of the 105
primary hits that were undetectable when analyzing mRNA
extracted from cells in 96-well plates, 71 reduced G6PC mRNA by
$30%; this gene cohort was therefore chosen as back-up hits. In
sum, our first confirmation assay verified 111 hits that markedly
reduced both target gene and G6PC expression and identified 85
back-up hits that would need to be ‘‘rescued’’ in a subsequent
assay to be considered confirmed.
To rescue target genes from amongst the above 85 back-up hits,
AH-G6PC cells were transfected with 7 distinct single siRNAs for
each of the 270 primary hits and changes in G6PC mRNA
expression were assayed with the previously described 4-gene
HTG ArrayPlate. We found that at least 2 single siRNAs for 192
of these 270 hits reduced G6PC expression in this assay (data not
shown). Based on these results, we were able to rescue 9 hits from
amongst the 14 back-up genes that reduced G6PC mRNA by 20–
30% in the pooled siRNA confirmation assay and 29 hits from
amongst the 71 back-up genes that were undetectable in the
pooled siRNA confirmation assay using mRNA extracted from 96-
well plate (Fig. 4B). Therefore, in total, we selected 149 primary
hits for further investigation including 111 from the pooled siRNA
Figure 4. Confirmation of primary screen hits by 2 distinct siRNA assays. A. Pooled siRNA knockdown of 165 Taqman-detectable primary
hits vs. reduction of G6PC mRNA expression as determined by Taqman qPCR analysis. Data are shown as fold change compared to mRNA expression
in siControl-transfected cells and are the means of a study performed in triplicate. The square contains 111 primary hits that reduce G6PC and target
gene expression by #0.7- and #0.8-fold, respectively. Red, blue, black, and green dots represent target gene knockdown by ,0.25-fold, between
0.25-fold to 0.5-fold, between 0.5-fold to 0.8-fold, and no knockdown, respectively. B. Schematic diagram for the 270 primary screen hits separated
into different categories after target gene knockdown study. Red represents the 111 hits identified above in A. Blue, orange, and light blue represent
primary hits that were not confirmed due to lack of G6PC knockdown. Sets of 7 distinct single siRNAs to each of the 270 primary screen hits were
tested for their ability to diminish G6PC expression using the 4-gene HTG platform to quantify mRNA levels. Any target gene for which $2 single
siRNAs reduced G6PC mRNA was deemed ‘‘rescued’’. This assay rescued 9 primary hits whose siRNA knocked down their target gene mRNA but only
reduced G6PC mRNA between 0.7- to 0.8-fold (purple) and 29 primary hits that were undetectable by Taqman analysis in the pooled siRNA
confirmation assay described in A, but were detectable using enriched cDNA as describe in the ‘‘Results’’ section (green). The blue squares label the
gene subsets that were combined to become our final 149 confirmed hits using the confirmation strategy described here. ND: undetectable by
Taqman analysis; KD: knockdown.
doi:10.1371/journal.pone.0036384.g004
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HTG assay.
Identification of GNG Inhibitors and Insulin Sensitizers
To investigate which of the 149 confirmed hits regulate
expression of key GNG genes in addition to G6PC, we developed
a 96-well HTG assay for G6PC, PEPCK, and PGC1a, once again
b-actin and ANT served as controls. Similar to G6PC, PEPCK
and PGC1a expressions in AH-G6PC cells were markedly
increased by Dex/cAMP and dose-dependently suppressed by
insulin (Fig. 5A). To be consistent with the primary screen, we
performed this 5-gene HTG assay using the same Dex/cAMP/
insulin treatment protocol and the primary screen siRNAs. The
activities of siRNA pools for each of the 149 hits were determined
in the assay. KD of the positive control, GR, reduced G6PC,
PGC1a, and PEPCK, mRNA expression by 0.62, 0.57 and 0.34-
fold compared to negative control, respectively (Fig. 5B). Because
the Dex/cAMP-induced assay windows for PEPCK and PGC1a
mRNAs were smaller than that for G6PC, we used 15% and 20%
reductions in PEPCK or PGC1a and G6PC, respectively, as the
cutoffs for hit selection. Of the 149 pooled siRNAs tested, 140
reduced G6PC expression $20%; of these, 76 and 99 also reduced
PEPCK and PGC1a mRNA levels $15%, respectively (Figs. 5C,
5D). Since 62 of the pooled siRNAs inhibited expression of all 3
genes, there were 14 siRNAs that only reduced G6PC and
PEPCK and 37 siRNAs that only reduced G6PC and PGC1a.
Together, the gene targets of these 113 siRNA pools that reduced
the expression of G6PC as well as PEPCK and/or PGC1a were
selected as our cohort of negative GNG gene regulators.
To investigate a potential mechanism by which the above 113
hits may have downregulated GNG gene expression, we developed
an Akt phosphorylation (Akt-p) assay to identify genes that
enhance insulin signaling in AH-G6PC cells when knocked down
by transfected siRNA. Chronic hyperinsulinemia has been shown
to reduce acute insulin induced Akt-p in hepatocytes [33]. The
multiplex electrochemiluminescent ELISA assay described in the
‘‘Experimental Procedures’’ section was used to quantify the
percentage of Akt-p vs total Akt (Akt-p%) that served as our
readout of insulin signaling. Acute (15 minute) insulin treatment of
AH-G6PC cells cultured in basal medium dose-dependently
increased Akt-p%, while cells cultured overnight with 100 nM
insulin (chronic insulin) became insulin resistant, displaying
significantly reduced Akt-p% in response to increasing concentra-
tions of acute insulin (Fig. 6A). Cells pre-incubated in basal media
responded to acute 10 nM insulin with a 35% greater increase in
Akt-p% than those that had undergone chronic insulin pre-
treatment. Cells transfected with siRNA pools targeting the 113
anti-gluconeogenic genes described above were cultured in insulin
overnight, washed, and subsequently treated acutely with insulin.
As expected, KD of known mediators of insulin resistance,
including PTEN, IKKb, or JNK1, increased Akt-p% by 193%,
54% and 44%, respectively (Fig. 6B). Amongst the pooled siRNAs
for the 113 negative GNG gene regulators we assayed, 61
increased Akt-p% by $15%, supporting the conclusion that KD of
these genes suppressed expression of GNG genes, at least partly,
by reversing insulin resistance and potentiating insulin signaling.
Therefore, these 61 hits were defined as ‘‘insulin sensitizers’’ while
the remaining 52 hits were defined as ‘‘GNG inhibitors’’ (Fig. 6C).
Figure 5. Use of a multiplex HTG assay to identify confirmed hit siRNA pools that decrease expression of key gluconeogenic genes
in addition to G6PC. A. Dex/cAMP increases and insulin dose-dependently reduces AH-G6PC cell PEPCK, PGC1a, and G6PC mRNA expression. Data
are presented as the means 6 SEM of fold change relative to untreated cells in 3 independent experiments. B. Knockdown of GR by siRNA
significantly reduces PEPCK, PGC1a, and G6PC mRNA in AH-G6PC cells incubated with Dex/cAMP and 10 nM insulin. Data are presented as the means
6 SEM of fold change relative to mRNA expression in siControl-transfected cells in 3 independent experiments. C. Subsets of pooled siRNAs targeting
confirmed hits regulate G6PC and PEPCK, or D. G6PC and PGC1a mRNA expression, in AH-G6PC cells treated with Dex/cAMP and 10 nM insulin. Data
in Figures 5C and 5D are plotted as fold change relative to mRNA expression in siControl-transfected cells and are the means of 3 independent
experiments. The squares contains siRNAs that reduced both G6PC and PEPCK (C) or G6PC and PGC1a (D) expression by 20% and 15%, respectively.
doi:10.1371/journal.pone.0036384.g005
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gene categories found within the insulin sensitizer and GNG
inhibitor target groups identified by our siRNA screening
procedure.
The siRNA screen described above identified 113 genes that
regulate the expression of key GNG genes. Therefore appropriate
pharmacological regulation of the proteins encoded by these genes
may reduce HGP and hyperglycemia in T2D patients. To further
evaluate the ability of our screen to identify targets that can be
pharmacologically manipulated to obtain anti-diabetic activity,
AH-G6PC cells were incubated with Dex/cAMP as in our siRNA
screen and co-treated with saturating concentrations of insulin
(400 nM) or the GR antagonist RU-483 (5 mM). Using the same
treatment conditions as the primary siRNA screen, Taqman
analysis of G6PC mRNA showed that RU486 significantly
lowered G6PC mRNA by 55%, while insulin reduced G6PC
mRNA by 90% (Fig. 7A). RU486 at 5 uM also reduced b-
lactamase activity in the cells, confirming a reduction in G6PC
promoter activity (data not shown). Gene expression analysis using
our 5-gene HTG assay platform showed that RU486 robustly
reduced G6PC, PEPCK and PGC1a expression in a manner
similar to insulin (Fig. 7B) and siRNA KD of GR as shown
previously in figure 5B. These results are in line with those
demonstrating that RU486 lowers hyperglycemia in diabetic mice
[29]. These data support the conclusion that pharmacological
effectors of the insulin sensitizer and anti-gluconeogenic targets
unveiled by the siRNA screening process reported here hold the
potential to serve as novel antidiabetic therapeutic agents.
Discussion
In order to aid in the discovery of new pharmacological agents
that promote insulin action and inhibit HGP, it is necessary to
continue identifying genes encoding druggable proteins that
regulate insulin sensitivity and GNG. To find such genes, we
developed a novel hormonally-responsive human hepatoma cell
line, AH-G6PC, and used it, together with a 4-gene HTG
ArrayPlate mRNA assay, to screen the pooled siRNAs comprising
a 6650 druggable gene library for their impact on the expression of
2 key GNG regulatory genes, G6PC and PDK4. Our initial screen
identified 614 primary hits that reduced G6PC mRNA expression
without increasing that of PDK4 in AH-G6PC cells treated
chronically with Dex/cAMP and insulin (Fig. 8). On basis of their
desirable chemical tractability and biology, we selected 270 of
Figure 6. Identification of insulin sensitizer and GNG inhibitor genes. A. Chronic (16 h) 100 nM insulin pretreatment reduces acute (15 min)
insulin induction of Akt phosphorylation (Akt-p) in AH-G6PC cells. Akt-p data are presented as the means 6 SEM of % Akt-p/total Akt from a
representative experiment performed in triplicate. B. Pooled siRNAs targeting JNK1, IKKb, or PTEN significantly potentiates acute insulin-induced Akt-
p after chronic insulin preincubation. Akt-p data are presented as the % Akt-p/total Akt relative to siControl-transfected cells (set as 100%) in response
to acute insulin treatment after chronic insulin preincubation and are the means 6 SEM of a representative experiment performed in triplicate. C.
Differential impact of pooled siRNAs targeting each of the 113 genes described in figures 5C and 5D in regulating G6PC mRNA expression vs.
potentiating insulin-induced Akt-p. Hits were separated into insulin sensitizers and GNG inhibitors that augmented acute insulin induction of Akt-p
by more and less than 15% (vertical line), respectively. Akt-p data are presented as the % Akt-p/total Akt relative to siControl-transfected cells (set as
100%) in response to acute insulin treatment after chronic insulin preincubation and are the means of 3 independent experiments. G6PC mRNA
expression data were obtained from figures 5C and 5D. D. Table summarizing the number of insulin sensitizer and GNG inhibitor hits in distinct
druggable gene categories.
doi:10.1371/journal.pone.0036384.g006
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using AH-G6PC cells treated pharmacologically as in our primary
screen. First, we developed a high-throughput Taqman qPCR
assay to determine the impact of the 270 pooled siRNAs on target
gene KD and G6PC mRNA expression in the same cellular
mRNA samples and used it to confirm 111 primary hits. We also
identified a cohort of 85 backup hits whose siRNA pools had a
notable but diminished inhibitory effect on G6PC mRNA
expression or that were expressed at relatively low levels in
comparison with our primary hit genes. Second, using our 4-gene
HTG ArrayPlate assay, we examined the effect of single siRNA
sets for each of our 270 primary hits on G6PC mRNA expression
and thereby rescued 38 of the backup hits described above. Thus,
together, these two assays confirmed 149 primary hits for further
investigation. To explore the ability of these targets genes to
regulate expression of key GNG genes in addition to G6PC, we
developed a second multiplex HTG ArrayPlate that allowed us to
analyze G6PC, PEPCK, and PGC1a expression in mRNA
obtained from AH-G6PC cells treated with pooled siRNAs as
well as Dex/cAMP and insulin as in our primary screen. We found
that amongst the siRNAs for the 149 confirmed hits, 113
downregulated G6PC and at least 1 of the 2 other GNG genes.
We then assayed the ability of pooled siRNAs targeting these 113
genes to augment insulin signaling in AH-G6PC cells that were
incubated chronically with insulin to induce insulin resistance as
determined by a diminution in acute insulin induction of Akt-p%.
We discovered that 61 siRNA pools potentiated acute insulin-
stimulated Akt-p%, thereby suggesting that their downregulation
of GNG genes was at least partially mediated by their
enhancement of insulin signaling. Finally, we demonstrated that
2 bona fide pharmacological inhibitors of GNG, the GR selective
antagonist RU486 and insulin, decreased Dex/cAMP induction of
G6PC, similarly to knocking down expression of GR or genes that
negatively regulate insulin signaling, thereby verifying the ability of
our screening procedure to identify druggable molecular targets
and their pharmacological effectors that can diminish GNG gene
expression and augment insulin action.
The screening of genome-wide siRNA libraries has become a
powerful tool to identify novel targets for the treatment of different
diseases [34]. Because most such screens generate hundreds of
primary hits, it is critical to discern the true hits and reduce the
number of false positives. The most commonly used method to
verify primary hits identified in screens utilizing siRNA pools, is to
remove ‘‘off-target’’ hits by testing the activity of sets of multiple
single siRNAs targeting each of these genes. Hits are then
generally considered confirmed if 2 or more single siRNA
reproduce the assay readout obtained in the primary screen. In
this way, primary hit genes selected due to off-target effects by a
single member of the pooled siRNA sets should be largely
eliminated. However, when we performed a pilot study using
groups of 4 single siRNAs targeting a number of primary hits that
are proven effectors of insulin signaling and/or GNG, we found
that this approach did not confirm all of these genes as hits, i.e., it
generated false negatives, due to diminished target gene KD in
comparison with pooled siRNAs. Therefore, for our first
confirmatory assay, we incubated cells with pooled siRNA sets
and then used high throughput Taqman analysis to quantify target
gene KD and reduction of G6PC mRNA expression. While many
primary hits were verified using this procedure, we also observed
that the mRNA of numerous targets could not be detected by
Taqman analysis apparently due to their relatively low expression
levels and the small amount of mRNA that could be extracted
from cells cultured in 96-well plates. However, by using enriched
mRNA extracted from AH-G6PC cells cultured in T75 flasks, we
were able to increase the sensitivity of our Taqman assay such that
we could identify a group of backup hits whose pooled siRNAs had
diminished G6PC mRNA expression in our first confirmatory
assay and now had detectable gene expression in AH-G6PC cells.
To further verify a subset of these backup hits as well as another
cohort identified in the first confirmatory assay, we utilized a
distinct combination of methods that included sets of 7 single
siRNA to KD target gene expression in AH-G6PC cells and 4-
gene HTG ArrayPlates to determine changes in G6PC mRNA
expression. By only rescuing hits when at least 2 of their single
siRNAs decreased G6PC mRNA levels, we felt confident that we
were not selecting false positives driven by off-target events. Also,
by using single siRNA KD at this step in the hit selection process,
we were not so concerned that important target genes would be
incorrectly filtered out as we would have been if it had been used
earlier when our overall confirmatory data was more limited.
Up until this point, our screening process had identified
numerous genes whose siRNAs reduced G6PC mRNA levels in
a hormone-responsive hepatoma cell line, thereby suggesting that
they might suppress HGP. However, since G6PC is only one of
several key genes involved in the regulation of HGP, we decided to
further filter our hit list by identifying those whose siRNAs also
diminished the expression of 2 other key GNG genes. To
accomplish this, we developed a multiplex HTG ArrayPlate assay
to quantify G6PC, PEPCK, and PGC1a mRNA expression. Our
data showed that ,75% of the pooled siRNAs tested reduced not
only G6PC mRNA expression in AH-G6PC cells, but that of at
least one of the other two GNG genes as well. Therefore, we
Figure 7. Pharmacological inhibitor of glucocorticoid receptor (GR) led to similar reduction of gluconeogenesis gene expression to
GR siRNA in AH-G6PC cell. AH-G6PC cells were preincubated with or without the GR antagonist RU486 (5 mM) for 18 h. The cells were then
incubated with Dex/cAMP alone, Dex/cAMP plus 400 nM insulin, or Dex/cAMP plus RU486 (in the cells treated with RU486 overnight) for 6 h. A.
Taqman analysis was performed on mRNA isolated from the cells to assay G6PC mRNA relative to Dex/cAMP treated cells. B. Multiplex HTG ArrayPlate
analysis of mRNA isolated from the cells was used to quantify PEPCK, PGC1a, and G6PC mRNA expression. Data are plotted as fold change vs. mRNA
levels in cells treated only with Dex/cAMP and are the means 6 SEM of 3 independent experiments.
doi:10.1371/journal.pone.0036384.g007
A Novel Approach to Identify Insulin Sensitizers
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36384concluded that the genes targeted by this subset of siRNAs were
potentially important regulators of GNG and, thus, HGP.
While elevated HGP is one important source of the hypergly-
cemia observed in T2D patients, another major cause is
diminished glucose uptake by skeletal muscle. Both of these
diabetic pathobiologies have been shown to result, in large part,
from obesity-induced insulin resistance in these tissues. It is
therefore reasonable to suggest that anti-diabetic agents with
optimal glucose lowering activity would not only suppress HGP by
directly inhibiting GNG like metformin and glucagon receptor
antagonists, but, preferably, enhance insulin sensitivity in liver and
skeletal muscle to both reduce HGP and potentiate insulin-
stimulated glucose uptake in the periphery. This hypothesis led us
to identify the confirmed hits whose siRNAs not only decreased
expression of key GNG genes but also enhanced insulin signaling.
Our results indicated that 54% of the pooled siRNA sets targeting
our aforementioned anti-GNG hits also potentiated acute insulin
stimulation of Akt phosphorylation in AH-G6PC cells made
insulin resistant by prior chronic insulin treatment. These 61
unique hits will be given high priority in future efforts to validate
novel anti-diabetic targets discovered by our screening procedure.
To further demonstrate the ability of our cell-based siRNA
screen to identify novel anti-diabetic drug targets, we examined
the impact of the GR antagonist RU486, a compound with proven
anti-gluconeogenic and glucose lowering activity in diabetic
animals [29], on GNG gene expression. We found that in AH-
G6PC cells treated chronically with Dex/cAMP, co-treatment
with RU486 reduced expression of G6PC, PEPCK and PGC1a
mRNA to levels comparable with those obtained with a saturating
concentration of insulin. These pharmacological results are in line
with antisense oligonucleotide studies demonstrating that liver-
specific KD of GR diminishes hepatic expression of G6PC and
PEPCK and lessens hyperglycemia in obese diabetic ob/ob and
db/db mice [35]. Antisense oligonucleotides targeted against
glucocorticoid receptor reduce hepatic glucose production and
ameliorate hyperglycemia in diabetic mice. In additional prelim-
inary studies, we identified small molecule effectors of protein
targets encoded by other confirmed target genes that reduced
expression of the 3 GNG genes in AH-G6PC cells to a similar
extent as RU486 (not shown). Furthermore, in an in vivo pilot
experiment one of these compounds, an enzyme inhibitor that was
previously unknown to regulate GNG gene expression or glucose
homeostasis, was able to significantly mitigate hyperglycemia in
db/db mice (not shown). On the basis of these results, we expect
that more of the hits identified in our siRNA screen will be
validated as novel anti-diabetic targets in diabetic animals using
both pharmacological and genetic protocols.
In summary, we have developed and performed a unique
druggable genome-wide siRNA screen in a hormonally-responsive
human hepatoma cell line that has identified genes whose protein
products possess noteworthy potential to serve as novel anti-
diabetic drug targets. Ongoing experimentation is currently
ongoing to further validate these prospective targets and identify
small molecule effectors possessing the appropriate characteristics
to be developed as efficacious and safe T2D therapeutics.
Materials and Methods
Generation of the AH-G6PC Cell Line
A clone of the Alexander hepatoma cell line (PLC/PRF/5
obtained from ATCC; #CRL-8024) that stably expresses b-
lactamase under the control of the human glucose-6-phosphatase
Figure 8. Schematic summary of the siRNA screening process that identified, confirmed, and characterized novel insulin sensitizer
and GNG inhibitor target genes.
doi:10.1371/journal.pone.0036384.g008
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G6PC promoter was PCR amplified (Advantage 2 PCR kit,
Clontech) from human genomic DNA using the following
primers: 59-GGC TCG AGA AGA CCA GCC TGG GCA
AC-39 and 59-CGC TCG AGT GAG TCT GTG CCT TGC
C-39. The reporter plasmid p7XUAS-BlaM-pcDNA3.1 (Aurora
Biosciences) was digested with Xho I to remove the 7XUAS
sequence and ligated with the PCR amplified human G6PC
promoter fragment to generate the reporter plasmid pG6PC-
BlaM-pcDNA3.1. Using Lipofectamine 2000 (Invitrogen),
pG6PC-BlaM-pcDNA3.1 was transfected into Alexander cells
plated into 10 cm
2 dishes at a cell density of 3.4610
6 in
Optimem 1 media (Invitrogen). Twenty four hours later the cells
were subcultured 1:4 in MEM Alpha Medium (Gibco) supple-
mented with 10% fetal bovine serum, 100 units/ml penicillin,
100 ug/ml streptomycin in the presence of 600 ug/ml Zeocin to
select for stable transfectants. The LiveBLAzer
TM FRET – B/G
Loading Kit (Invitrogen) was used to asaay +/21 uM Dex/
100 uM 8-CPT cAMP using CCF2-AM to label the live cells
with b-lactamase negative cells with a green fluorescence signal
and b-lactamase positive cells with a blue fluorescence signal.
FACS sorting analysis was used to identify stable transfectants
with blue fluorescence signals. Positive cells were grown up and
then subcloned by limiting dilution to generate the cloned AH-
G6PC cell line. These cells were maintained in the growth
medium (MEM Alpha Medium (Gibco) supplemented with 10%
fetal bovine serum, 100 units/ml penicillin, 100 ug/ml strepto-
mycin and 0.15 mg/ml Zeocin), at 37uCi n5 %C O 2.
Gene Expression, siRNA Transfection, b-lactamase, and
AKT Phosphorylation Assays
Individual siGENOME and SMARTpool siRNAs from
Dharmacon were used to KD all genes of interest. In 96-well
plates, 20,000 AH-G6PC cells/well were reverse-transfected
using Dharmafect1 transfection reagent (Dharmacon) following
the manual instruction. Briefly, DharmaFect1 (0.25 ul per well)
was mixed with 24.75 ul OPTIMEM medium for 5 minutes
and then combined with 25 ul OPTIMEM medium with
siRNA (0.375 ul of 20 uM stock). The mixture was incubated
for 20 minutes and added to each well, and then 100 ul of cell
suspension (2610
5 cells/ml) in growth medium was added to
each well. The final siRNA concentration in the transfection
mix was 50 nM. After a 24 h incubation with siRNA, the
transfection mix was removed, and the cells were allowed to
recover in the growth medium for 5 h. The cells were then
serum starved for 16 h, and subsequently treated with 0.5 mM
dexamethasone, 100 mM 8-CPT cAMP, and 10 nM insulin in
serum-free media for 6 h. Total mRNA or total RNA was
isolated from cells using Turbocapture96 mRNA Plates or
RNeasy 96-well mini-kit according to protocols provided by the
manufacturer, respectively (Qiagen). cDNA was synthesized with
the iScript cDNA Synthesis Kit (BioRad). Amplification of each
target cDNA was performed with the Taqman PCR Reagent
Kit in an ABI Prism 7900 Sequence Detection System (PE
Applied Biosystems) with a program of 40 cycles, each cycle
consisting of 95uC for 15 seconds and 60uC for one minute.
Taqman qPCR data were analyzed using RQ Manager 1.2
(Applied Biosystems), with automatic baseline and manual
threshold setting at 0.2 to generate Ct values. Genes with a
Ct $36 were considered undetectable. The ??Ct method was
used to calculate the relative expression level and gene KD.
G6PC mRNA levels were normalized by the amount of b-actin
mRNA detected in each sample. b-lactamase was measured
using the LyticBLAzer_h-BODIPY FL Kit according to
protocols provided by the manufacturer (Invitrogen). Akt
proteins were analyzed using a multiplex electroluminescence
assay kit detecting Akt phosphorylated at Ser-473 and total Akt
following the manual instruction (Meso Scale Discovery).
Primary siRNA Screen and Multiplex Gene Expression
using a High-Throughput Genomics (HTG) ArrayPlate
In a 384-well plate, 5000 AH-G6PC cells were reverse-
transfected with 20 nM siControl non-targeting siRNA (Dharma-
con) and 6650 druggable siRNA pools (3 siRNA/pool) (Sigma
Mission human druggable genome) using Dharmafect-1 (Dhar-
macon) as described previously with 0.1 ul DharmaFect1, siRNAs,
and 10 ul OPTIMEM per well. The cells were then incubated at
37uC for 24 h post-transfection, after which the growth media was
replaced with MEM Alpha supplemented with 10% serum for 5 h.
The cells were subsequently incubated with serum free MEM
Alpha overnight. Lastly, the medium was changed to serum free
MEM Alpha with 100 mM 8CPT-cAMP, 0.5 mM dexamethasone,
and 10 nM insulin (Sigma) for 6 h.
A high throughput multiplex quantitative nuclease protection
assay (qNPA) was performed on the treated cells as previously
described [36] to simultaneously measure mRNA expression of
G6PC, PDK4, b-actin, and a negative control plant gene, ANT.
Media was removed from the cell culture plates and a
proprietary lysis reagent (High Throughput Genomics) is added
(12.5 ul) to lyse the cells, overlayed with denaturation oil (35 ul),
A cocktail of nuclease protection probes (NPP, synthetic
biotinylated DNA that complements the RNA of the target
gene being measured) were added and incubated at 95uC for 10
minutes in oven then cooled down to room temperature and
incubated at 50uC for 6 hours. S1 nuclease (10 ul) was added
and incubated for 50 minutes at 60uC, during which time all
the nonspecific RNA, DNA and excess single stranded nuclease
protection probes are destroyed such that only the specific
probe/target hybrid duplexes remained. Sodium hydroxide was
then added and the sample heated at 95uC for 10 minutes to
dissociate the probes from the target RNA and destroy the
released target RNA. The solution was neutralized and
transferred onto the programmed 96-well 4-gene HTG
ArrayPlate (High Throughput Genomics). NPP probes were
captured during an overnight incubation at 50uC. The media
was removed and a cocktail of NPP-specific detection linkers
were added, which hybridized to their respective captured NPP
during a 1 hour incubation at 60uC. The array was then
washed and a HRP-labeled oligonucleotide detection probe was
added and incubated at 37uC for 1 hour; the array was then
washed again to remove unbound detection probe. Luminescent
peroxidase substrate (Atto-PS
TM, Lumigen) was added and the
plate imaged for 15 sec. to measure the intensity of every
element within the plate. Imaging was carried out using the
Omix Imager (HTG Molecular), which images all wells of an
entire plate at the same time. The intensity from each
individual element of the array was measured. The position
within the array identified the gene being measured, and the
amount of luminescence from each element indicated the
amount of each gene. The Omix software ‘‘extracts’’ the data
from the images, quantifying each element, and then permitting
analysis such as subtraction of background and normalization to
b-actin. A second multiplex HTG ArrayPlate assay was used to
identify target genes that when knocked down affect expression
of PGC1a and PEPCK in addition to G6PC; b-actin, and
negative ANT once again served as controls genes. The assay
was performed in the same manner as described above.
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Gene Knockdown
AH-G6PC cells were transfected with pooled siRNA (3/gene) to
each of 270 primary assay gene hits in 96-well plates. After
transfection and treatment of the cells as described above, mRNA
was extracted followed by cDNA synthesis to prepare the samples
for Taqman qPCR analysis. For test gene KD analysis, cells
transfected by a negative control siRNA (siControl) were processed
in parallel and used as a calibrator for calculating the level of test
gene KD. Two hundred seventy distinct Taqman gene expression
assays and Gene Expression Master Mix (Applied Biosystems)
were custom pre-plated in 384-well PCR plates, with the Taqman
assay well locations matching the locations of corresponding
siRNA samples. b-actin Taqman assay (Applied Biosystems) was
also pre-plated in 384-well PCR plates for measuring b-actin
cDNA in all samples. For each primary hit, we ran Taqman qPCR
of the target gene and b-actin control in triplicate for both siRNA-
and siControl-transfected samples. For Taqman qPCR reactions,
2 ul of cDNA was transferred to the 8 ul Taqman assay and Gene
Expression Master Mix using Biomek FX liquid handler (Beckman
Coulter). PCR amplifications and fluorescence detection was
conducted in an Applied Biosystems 7900HT sequence detector
with a program of 40 cycles as described above.
Statistical Analysis of Primary siRNA Screening Data
Data quality was assured through implementing quality control
procedures as described previously [37]. We calculated the
average fold change and strictly standardized mean difference
(SSMD) for all siRNAs (Zhang, 2011). As previously described,
SSMD is the ratio of mean and standard deviation of a difference
[38]. We then selected hits using a dual-flashlight plot in which
both average fold-change and SSMD were considered simulta-
neously [39]. In the primary screen described previously, we first
used the criterion of average fold change in G6PC expression of
$2 and SSMD $1 for selecting up-regulators and average fold
change in G6PC mRNA expression of #0.5 and SSMD#21 for
selecting down-regulators. To rescue hits with consistent but not
very strong average activity, we further used the criterion of
SSMD $2 and an average increase of between 30% and 200% in
G6PC mRNA expression for selecting additional up-regulators
and SSMD#22 and an average reduction of between 30% and
200% in G6PC mRNA expression for selecting additional down-
regulators (Fig. 2C).
Acknowledgments
We thank Nancy Thornberry for her support and encouragement during
the performance of the studies presented here. We also thank John
Vaillancourt, Shane Marine, Richard Chen, KellyAnn D. Pryor, Chuanlin
Wang, Eugen Buehler, Eric Minch, John Thompson, Heather Zhou for
their contributions and supports to this manuscript.
Author Contributions
Conceived and designed the experiments: RY BZ JB SQ KKQ MF.
Performed the experiments: RY RGL GC YL. Analyzed the data: XDZ
LMC WZ RY. Contributed reagents/materials/analysis tools: ME. Wrote
the paper: RY JB.
References
1. Saltiel AR (2001) New perspectives into the molecular pathogenesis and
treatment of type 2 diabetes. Cell 104: 517–529.
2. Yang R, Trevillyan JM (2008) c-Jun N-terminal kinase pathways in diabetes.
Int J Biochem Cell Biol 40: 2702–2706.
3. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the
diabetes epidemic. Nature 414: 782–787.
4. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, et al. (2000) Mechanism
by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:
2063–2069.
5. Mithieux G, Guignot L, Bordet JC, Wiernsperger N (2002) Intrahepatic
mechanisms underlying the effect of metformin in decreasing basal glucose
production in rats fed a high-fat diet. Diabetes 51: 139–143.
6. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995) Metabolic
effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med
333: 550–554.
7. Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism.
Am J Physiol Endocrinol Metab 284: E671–678.
8. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, et al. (1994)
Immunoneutralization of endogenous glucagon with monoclonal glucagon
antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats.
Diabetologia 37: 985–993.
9. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, et al. (2004)
Reduction in glucagon receptor expression by an antisense oligonucleotide
ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410–417.
10. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, et al. (2004)
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon
receptor antisense oligonucleotide inhibitors. J Clin Invest 113: 1571–1581.
11. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D (1982)
Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist.
Science 215: 1115–1116.
12. Kim RM, Chang J, Lins AR, Brady E, Candelore MR, et al. (2008) Discovery of
potent, orally active benzimidazole glucagon receptor antagonists. Bioorg Med
Chem Lett 18: 3701–3705.
13. Sloop KW, Michael MD, Moyers JS (2005) Glucagon as a target for the
treatment of Type 2 diabetes. Expert Opin Ther Targets 9: 593–600.
14. Lau J, Behrens C, Sidelmann UG, Knudsen LB, Lundt B, et al. (2007) New
beta-alanine derivatives are orally available glucagon receptor antagonists. J Med
Chem 50: 113–128.
15. Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, et al. (2004) A novel
glucagon receptor antagonist inhibits glucagon-mediated biological effects.
Diabetes 53: 3267–3273.
16. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, et al. (2000) Loss
of insulin signaling in hepatocytes leads to severe insulin resistance and
progressive hepatic dysfunction. Mol Cell 6: 87–97.
17. Fisher SJ, Kahn CR (2003) Insulin signaling is required for insulin’s direct and
indirect action on hepatic glucose production. J Clin Invest 111: 463–468.
18. Foufelle F, Ferre P (2002) New perspectives in the regulation of hepatic
glycolytic and lipogenic genes by insulin and glucose: a role for the transcription
factor sterol regulatory element binding protein-1c. Biochem J 366: 377–391.
19. Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism,
differentiation, and transformation. Cell 117: 421–426.
20. Cichy SB, Uddin S, Danilkovich A, Guo S, Klippel A, et al. (1998) Protein
kinase B/Akt mediates effects of insulin on hepatic insulin-like growth factor-
binding protein-1 gene expression through a conserved insulin response
sequence. J Biol Chem 273: 6482–6487.
21. Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, et al. (1999)
FKHR binds the insulin response element in the insulin-like growth factor
binding protein-1 promoter. Endocrinology 140: 3140–3146.
22. Tang ED, Nunez G, Barr FG, Guan KL (1999) Negative regulation of the
forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741–16746.
23. Guo S, Rena G, Cichy S, He X, Cohen P, et al. (1999) Phosphorylation of serine
256 by protein kinase B disrupts transactivation by FKHR and mediates effects
of insulin on insulin-like growth factor-binding protein-1 promoter activity
through a conserved insulin response sequence. J Biol Chem 274: 17184–17192.
24. Biggs WH, 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC (1999)
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of
the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 96:
7421–7426.
25. Nakae J, Park BC, Accili D (1999) Insulin stimulates phosphorylation of the
forkhead transcription factor FKHR on serine 253 through a Wortmannin-
sensitive pathway. J Biol Chem 274: 15982–15985.
26. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, et al. (2001) Control of
hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature
413: 131–138.
27. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, et al. (2003) Insulin-
regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction.
Nature 423: 550–555.
28. Li X, Monks B, Ge Q, Birnbaum MJ (2007) Akt/PKB regulates hepatic
metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature
447: 1012–1016.
29. Friedman JE, Sun Y, Ishizuka T, Farrell CJ, McCormack SE, et al. (1997)
Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglyce-
mia are regulated by glucocorticoids in genetically obese db/db transgenic mice.
J Biol Chem 272: 31475–31481.
A Novel Approach to Identify Insulin Sensitizers
PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e3638430. Barthel A, Schmoll D (2003) Novel concepts in insulin regulation of hepatic
gluconeogenesis. Am J Physiol Endocrinol Metab 285: E685–692.
31. Huang B, Wu P, Bowker-Kinley MM, Harris RA (2002) Regulation of pyruvate
dehydrogenase kinase expression by peroxisome proliferator-activated receptor-
alpha ligands, glucocorticoids, and insulin. Diabetes 51: 276–283.
32. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:
860–867.
33. Saad MJ, Folli F, Kahn CR (1995) Insulin and dexamethasone regulate insulin
receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao
hepatoma cells. Endocrinology 136: 1579–1588.
34. Rondinone CM (2006) Minireview: ribonucleic acid interference for the
identification of new targets for the treatment of metabolic diseases.
Endocrinology 147: 2650–2656.
35. Liang Y, Osborne MC, Monia BP, Bhanot S, Watts LM, et al. (2005) Antisense
oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose
production and ameliorate hyperglycemia in diabetic mice. Metabolism 54:
848–855.
36. Martel RR, Botros IW, Rounseville MP, Hinton JP, Staples RR, et al. (2002)
Multiplexed screening assay for mRNA combining nuclease protection with
luminescent array detection. Assay Drug Dev Technol 1: 61–71.
37. Zhang XD (2008) Novel analytic criteria and effective plate designs for quality
control in genome-scale RNAi screens. J Biomol Screen 13: 363–377.
38. Zhang XD (2007) A new method with flexible and balanced control of false
negatives and false positives for hit selection in RNA interference high-
throughput screening assays. J Biomol Screen 12: 645–655.
39. Zhang XD (2010) Assessing the size of gene or RNAi effects in multifactor high-
throughput experiments. Pharmacogenomics 11: 199–213.
A Novel Approach to Identify Insulin Sensitizers
PLoS ONE | www.plosone.org 13 May 2012 | Volume 7 | Issue 5 | e36384